Oportuzumab monatox (OM), an ADC that uses Pseudomonas exotoxin A (ETA 252-608) as a cytotoxic agent and targets EpCAM expressing tumor cells, has shown potential as an intravesical therapeutic agent (16). Here, EPCAM is linked to neoplasm.